Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells

Journal of Orthopaedic Research

Volumn 29, Issue 9, 2011, Pages 1327-1335

  Papathanasopoulos, Argiris ^a   Kouroupis, Dimitrios ^a   Henshaw, Karen ^a   McGonagle, Dennis ^a   Jones, Elena A ^a   Giannoudis, Peter V ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

bone healing; chemical thromboprophylaxis; low molecular heparins; MSC

Indexed keywords

5' NUCLEOTIDASE; ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; CD146 ANTIGEN; COLLAGENASE; ENDOGLIN; FONDAPARINUX; TINZAPARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CARTILAGE CELL; CELL COUNT; CELL DIFFERENTIATION; CELL GROWTH; CELL ISOLATION; CELL POPULATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING UNIT; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME RELEASE; FEMALE; FIBROBLAST; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MESENCHYMAL STEM CELL; NITROBLUE TETRAZOLIUM TEST; OSTEOBLAST; PHENOTYPE; PRIORITY JOURNAL; TRABECULAR BONE;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; CHONDROGENESIS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MESENCHYMAL STEM CELLS; MIDDLE AGED; OSTEOGENESIS; POLYSACCHARIDES; YOUNG ADULT;

EID: 79960220381     PISSN: 07360266     EISSN: 1554527X     Source Type: Journal    
DOI: 10.1002/jor.21405     Document Type: Article

References (35)

1. Abelseth G, Buckley RE, Pineo GE, et al. 1996. Incidence of deep-vein thrombosis in patients with fractures of the lower extremity distal to the hip. J Orthop Trauma 10 (4): 230-235. (Pubitemid 126432695)
2. Colwell CW Jr, Spiro TE,. 1995. Efficacy and safety of enoxaparin to prevent deep vein thrombosis after hip arthroplasty. Clin Orthop 319: 215-222.
3. Francis CW, Pellegrini VD Jr, Totterman S, et al. 1997. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone Joint Surg Am 79: 1365-1372. (Pubitemid 27413166)
4. Moskovitz PA, Ellenberg SS, Feffer HL, et al. 1978. Low dose heparin for prevention of venous thromboembolism in total hip arthroplasty and surgical repair of hip fractures. J Bone Joint Surg Am 60 (8): 1065-1070. (Pubitemid 9104498)
5. Teitelbaum SL,. 2010. Stem cells and osteoporosis therapy. Cell Stem Cell 7 (5): 553-554.
6. Nikolaou VS, Efstathopoulos N, Kontakis G, et al. 2009. The influence of osteoporosis in femoral fracture healing time. Injury 40 (6): 663-668.
7. Johansen A, Evans RJ, Stone MD, et al. 1997. Fracture incidence in England and Wales: a study based on the population in Cardiff. Injury 28 (9-10): 655-660. (Pubitemid 28185117)
8. Chakkalakal DA, Novak JR, Fritz ED, et al. 2005. Inhibition of bone repair in a rat model for chronic and excessive alcohol consumption. Alcohol 36 (3): 201-214. (Pubitemid 41827943)
9. Porter SE, Hanley EN Jr., 2001. The musculoskeletal effects of smoking. J Am Acad Orthop Surg 9 (1): 9-17.
10. Pountos I, Georgouli T, Blokhuis TJ, et al. 2008. Pharmacological agents and impairment of fracture healing: what is the evidence? Injury 39 (4): 384-394.
11. Muir JM, Hirsh J, Weitz JI, et al. 1997. A histomorphometric comparison of the effects of heparin and low molecular-weight heparin on cancellous bone in rats. Blood 89 (9): 3236-3242.
12. Hunt BJ, Doughty HA, Majumdar G, et al. 1997. Tromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 77 (1): 39-43. (Pubitemid 27064965)
13. Sivakumaran M, Ghosh K, Zaidi Y, et al. 1996. Osteoporosis and vertebral collapse following low-dose, low molecular weight heparin therapy in a young patient. Clin Lab Haematol 18 (1): 55-57. (Pubitemid 26126231)
14. Handschin AE, Trentz OA, Hoerstrup SP, et al. 2005. Effect of low molecular-weight heparin (dalteparin) and fondaparinux (arixtra) on human osteoblasts in vitro. Br J Surg 92 (2): 177-183. (Pubitemid 40269331)
15. Matziolis G, Perka C, Disch A, et al. 2003. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts. Calcif Tissue Int 73 (4): 370-379. (Pubitemid 37409424)
16. Sakaguchi Y, Sekiya I, Yagishita K, et al. 2004. Suspended cells from trabecular bone by collagenase digestion become virtually identical to mesenchymal stem cells obtained from marrow aspirates. Blood 104 (9): 2728-2735. (Pubitemid 39434954)
17. Jones E, English A, Churchman SM, et al. 2010. Large-scale extraction and characterization of CD271(+) multipotential stromal cells from trabecular bone in health and osteoarthritis: implications for bone regeneration strategies based on minimally-cultured multipotential stromal cells. Arthritis Rheum 62 (7): 1944-1954.
18. Jones EA, English A, Henshaw K, et al. 2004. Enumeration and phenotypic characterization of synovial fluid multipotential mesenchymal progenitor cells in inflammatory and degenerative arthritis. Arthritis Rheum 50 (3): 817-827. (Pubitemid 38326182)
19. Jones EA, Kinsey SE, English A, et al. 2002. Isolation and characterization of bone marrow multipotential mesenchymal progenitor cells. Arthritis Rheum 46 (12): 3349-3360. (Pubitemid 35453547)
20. Pountos I, Giannoudis PV, Jones E, et al. 2010. NSAIDS inhibit in vitro MSC chondrogenesis but not osteogenesis. J Cell Mol Med [Epub ahead of print].
21. Jones EA, Crawford A, English A, et al. 2008. Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis Rheum 58 (6): 1731-1740. (Pubitemid 351847527)
22. Wagner W, Horn P, Castoldi M, et al. 2008. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLoS ONE 3 (5): e2213.
23. Pountos I, Jones EA, Tzioupis C, et al. 2006. Growing bone and cartilage: the role of mesenchymal stem cells. J Bone Joint Surg Br 88 (4): 421-426.
24. Tuli R, Tuli S, Nandi S, et al. 2003. Characterization of multipotential mesenchymal progenitor cells derived from human trabecular bone. Stem Cells 21 (6): 681-693. (Pubitemid 37329161)
25. Nöth U, Osyczka AM, Tuli R, et al. 2002. Multilineage mesenchymal differentiation potential of human trabecular bone-derived cells. J Orthop Res 20 (5): 1060-1069.
26. Baxter MA, Wynn RF, Jowitt SN, et al. 2004. Study of telomere length reveals rapid aging of human marrow stromal cells following in vitro expansion. Stem Cells 22 (5): 675-682. (Pubitemid 39172200)
27. Hirsh J, Bauer KA, Donati MB, et al. 2008. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 Suppl): 141S-159S. Erratum in: Chest 2008; 134(2): 473. (Pubitemid 351892966)
28. Depasse F, Gonzalez de Suso MJ, Lagoutte I, et al. 2003. Comparative study of the pharmacokinetic profiles of two LMWHs-bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa)-administered subcutaneously to healthy male volunteers. Thromb Res 109 (2-3): 109-117. (Pubitemid 36428761)
29. Rajgopal R, Bear M, Butcher MK, et al. 2008. The effects of heparin and low molecular weight heparins on bone. Thromb Res 122 (3): 293-298. (Pubitemid 351888881)
30. Young E, Wells P, Holloway S, et al. 1994. Ex-vivo and in vitro evidence that low-molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 71 (3): 300-304. (Pubitemid 24083739)
31. Hirsh J, Warkentin TE, Raschke R, et al. 1999. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 114 (5 Suppl): 489S-510S. Erratum in: Chest 1999; 115(6): 1760.
32. Canalis E, McCarthy T, Centrella M,. 1988. Isolation and characterization of insulin-like growth factor I (somatomedin-C) from cultures of fetal rat calvariae. Endocrinology 122 (1): 22-27. (Pubitemid 18027578)
33. Andress DL,. 1995. Heparin modulates the binding of insuline-like growth factor (IGF) binding protein-5 to a membrane protein in osteoblastic cells. J Biol Chem 270 (47): 28289-28296.
34. Heinzelmann M, Bosshart H,. 2004. Fondaparinux sodium lacks immunomodulatory effects of heparin. Am J Surg 187 (1): 111-113. (Pubitemid 38045515)
35. Street JT, McGrath M, O'Regan K, et al. 2000. Thromboprophylaxis using a low molecular weight heparin delays fracture repair. Clin Orthop Relat Res 381: 278-289.